electroCore, Inc. is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve. gammaCore is cleared or approved for use in both the acute and preventative treatment of primary headache disorders, including cluster headache and migraine. The device has obtained U.S. Food and Drug Administration clearance, as well as CE mark approval in Europe, enabling electroCore to serve patients and healthcare providers in multiple major markets.
In addition to its commercial offerings for headache disorders, electroCore is actively exploring broader applications of its nVNS platform. Ongoing clinical trials and research collaborations are evaluating gammaCore in areas such as inflammatory respiratory conditions and gastrointestinal disorders. The company’s strategy involves leveraging its established regulatory approvals and real-world evidence to pursue label expansions and new indications.
electroCore operates in the United States and Europe, working with headache specialists, neurologists, and pain management clinics to integrate nVNS into treatment paradigms. The company is led by a management team with backgrounds in medical device development, neurology, and regulatory affairs, supported by a board of directors with expertise in biopharmaceutical innovation. Through strategic partnerships and clinical research, electroCore aims to expand access to non‐invasive neuromodulation therapies and advance the field of bioelectronic medicine.
AI Generated. May Contain Errors.
Free ECOR Stock Alerts